Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-7386 + darolutamide versus darolutamide alone before prostatectomy in localized prostate cancer
ACTRN12623000160639Phase 2Not yet recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of masofaniten and darolutamide in prostate cancer (PCa) (2 arms), sponsored by St Vincent's Hospital Sydney. Primary endpoint: Complete pathological response rate. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
masofanitendarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12623000160639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000160639.